Welcome to our dedicated page for Dr Reddys Labs SEC filings (Ticker: RDY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Dr. Reddy's Laboratories Limited (RDY) SEC filings page on Stock Titan brings together the company’s U.S. regulatory disclosures as a foreign private issuer listed on the New York Stock Exchange. Dr. Reddy's files reports such as Form 6-K with the Securities and Exchange Commission, providing investors with access to financial results, board and corporate actions, and other information furnished under its home-country requirements.
Key filing types for Dr. Reddy's include periodic Form 6-K submissions that often attach consolidated IFRS financial statements, segment data for Global Generics and Pharmaceutical Services and Active Ingredients (PSAI), and management commentary on revenue trends, R&D spending and regional performance. These filings can also include intimations regarding board meetings, corporate actions and other material updates first disclosed in India.
For a pharmaceutical manufacturer active in APIs, generics, branded generics, biosimilars and OTC products, SEC filings are a primary source for understanding segment performance, geographic mix and investment in R&D. Investors can use them to track how Dr. Reddy's generics and biosimilars portfolios evolve, how collaborations and acquisitions contribute to results, and how the company allocates capital across regions and product categories.
On Stock Titan, each new RDY filing from EDGAR is captured and organized chronologically. AI-powered summaries help explain the main points of lengthy documents, highlighting items such as revenue movements, margin changes, R&D focus areas and notable regulatory or ESG disclosures. Users can quickly scan these summaries before diving into the full text of a 6-K or related exhibits.
In addition to financial information, this page can surface filings that relate to governance, risk and compliance, complementing press releases about inspections, recalls or ESG recognitions. Together, these documents provide a structured view of Dr. Reddy's regulatory footprint in the U.S. and support deeper analysis of the RDY stock for research-oriented investors.
Dr. Reddy’s Laboratories (RDY) reported interim results for the quarter and six months ended September 30, 2025. Six‑month revenues were Rs. 173,503 million with profit of Rs. 28,364 million; basic EPS was Rs. 34.30. For the quarter, revenues were Rs. 88,051 million and profit was Rs. 14,268 million.
Gross profit for six months reached Rs. 96,767 million against operating expenses of Rs. 61,779 million, yielding operating profit of Rs. 34,988 million. The effective tax rate was 24.2% for six months. Operating cash flow was Rs. 30,202 million; cash and cash equivalents stood at Rs. 9,906 million with other investments of Rs. 64,487 million.
By segment (six months), Global Generics delivered Rs. 154,118 million revenue; PSAI contributed Rs. 17,631 million. By geography, revenues were United States Rs. 69,958 million, India Rs. 31,781 million, Russia Rs. 15,829 million, and Others Rs. 55,935 million. The balance sheet showed total assets Rs. 542,005 million, equity Rs. 362,082 million, short‑term borrowings Rs. 41,155 million and long‑term borrowings Rs. 17,384 million. The company paid a dividend of Rs. 6,659 million and recorded inventory write‑downs of Rs. 3,450 million over six months.
Amendment No. 6 to Schedule 13D reports ownership and transfer details for DR REDDY'S LABORATORIES LTD ADSs (ticker RDY). On September 17, 2025, G.V. Prasad transferred 96,095,920 post-split shares to GVP Family Trust and K. Satish Reddy transferred 75,630,620 post-split shares to VSD Family Trust for estate planning and family succession. After these transfers, reporting persons may be deemed to beneficially own between approximately 9.07% and 13.58% of outstanding post-split shares depending on constructive ownership through trusts and HUFs. The filing explains source of shares (merger-related distributions, prior transfers, inheritance) and trust deeds that include ROFR and tag-along rights.